Literature DB >> 15301566

Paclitaxel in early breast cancer: a viewpoint by Aman U. Buzdar.

Aman U Buzdar1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15301566     DOI： 10.2165/00003495-200464160-00009

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


× No keyword cloud information.
  10 in total

1.  A phase III trial of sequential adjuvant chemotherapy for operable breast carcinoma: final analysis with 10-year follow-up.

Authors:  Vasily Assikis; Aman Buzdar; Ying Yang; Terry Smith; Richard Theriault; Daniel Booser; Vicente Valero; Ronald Walters; Eva Singletary; Frederick Ames; Gabriel Hortobagyi
Journal:  Cancer       Date:  2003-06-01       Impact factor: 6.860

2.  Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer.

Authors:  F A Holmes; R S Walters; R L Theriault; A D Forman; L K Newton; M N Raber; A U Buzdar; D K Frye; G N Hortobagyi
Journal:  J Natl Cancer Inst       Date:  1991-12-18       Impact factor: 13.506

3.  Phase II evaluation of vinblastine, methotrexate, and calcium leukovorin rescue in patients with refractory metastatic breast cancer.

Authors:  G N Hortobagyi; H Y Yap; G R Blumenschein; A U Buzdar; B C Barnes; S S Legha; C L Wiseman
Journal:  Cancer       Date:  1983-03-01       Impact factor: 6.860

4.  Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer.

Authors:  J F Bishop; J Dewar; G C Toner; J Smith; M H Tattersall; I N Olver; S Ackland; I Kennedy; D Goldstein; H Gurney; E Walpole; J Levi; J Stephenson; R Canetta
Journal:  J Clin Oncol       Date:  1999-08       Impact factor: 44.544

5.  Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.

Authors:  M N Levine; V H Bramwell; K I Pritchard; B D Norris; L E Shepherd; H Abu-Zahra; B Findlay; D Warr; D Bowman; J Myles; A Arnold; T Vandenberg; R MacKenzie; J Robert; J Ottaway; M Burnell; C K Williams; D Tu
Journal:  J Clin Oncol       Date:  1998-08       Impact factor: 44.544

6.  Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.

Authors:  J L Misset; M di Palma; M Delgado; R Plagne; P Chollet; P Fumoleau; B Le Mevel; D Belpomme; J Guerrin; P Fargeot; R Metz; M Ithzaki; C Hill; G Mathé
Journal:  J Clin Oncol       Date:  1996-04       Impact factor: 44.544

7.  Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer.

Authors:  B S Reichman; A D Seidman; J P Crown; R Heelan; T B Hakes; D E Lebwohl; T A Gilewski; A Surbone; V Currie; C A Hudis
Journal:  J Clin Oncol       Date:  1993-10       Impact factor: 44.544

8.  Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy.

Authors:  Bita Esmaeli; Lillie Hidaji; Rosnie B Adinin; Misha Faustina; Carol Coats; Rebecca Arbuckle; Edgardo Rivera; Vicente Valero; Shi-Ming Tu; M Amir Ahmadi
Journal:  Cancer       Date:  2003-08-01       Impact factor: 6.860

9.  Combined modality treatment of stage III and inflammatory breast cancer. M.D. Anderson Cancer Center experience.

Authors:  A U Buzdar; S E Singletary; D J Booser; D K Frye; B Wasaff; G N Hortobagyi
Journal:  Surg Oncol Clin N Am       Date:  1995-10       Impact factor: 3.495

10.  Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

Authors: 
Journal:  Lancet       Date:  1998-09-19       Impact factor: 79.321
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.